Achievement of Better Examinee Compliance on Colon Cleansing Using Commercialized Low-Residue Diet

Sponsor
National Taiwan University Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT00748293
Collaborator
Taipei Medical University Hospital (Other), E-DA Hospital (Other), Buddhist Tzu Chi General Hospital (Other), En Chu Kong Hospital (Other)
224
5
2
4
44.8
11.2

Study Details

Study Description

Brief Summary

Good colon cleansing is pivotal for achieving speedy and safe colonoscopic examination with high adenoma detection rate.Previous studies, including our previous RCT conducted in 2004 to 2005, have demonstrated that high yield rate can be achieved by on-the-day colon preparation with 2000 ml PEG-ELS. Poor patient compliance, however, is the main hurdle to complete ingestion of 2000 ml PEG-ELS not only for subjects with lower body weight but also for those with normal BMI or body weight.The main cause of poor patient compliance includes abdominal pain, bloating, nausea or vomiting during ingestion of cleansing fluid.Though diet restriction with low-fiber diet is always advised to every screen before colonoscopy, the extent of diet restriction is widely variable and thus influences the degree of colon cleansing.

With commercialized low-residue diet (CLRD), diet restriction will be well controlled and variability of colon cleansing can be minimized such that guarantee a colonoscopy with good quality. In this RCT, we will compare the compliance of screen during colon cleansing using different protocol: namely 2000 ml PEG-ELS vs. 1500 ml plus low-residue diet.

Condition or Disease Intervention/Treatment Phase
  • Other: Low-residue diet
N/A

Detailed Description

Setting: A multi-center study including the following teaching hospitals:

National Taiwan University Hospital, Taipei Taipei Medical University Hospital, Taipei E-Da Hospital, Kaohsiung Buddhist Tzu-Chi General Hospital, Taipei En Chu Kong Hospital, Taipei Far Eastern Memorial Hospital, Taipei

Study design: RCT, single blinded

Study subjects:

Inclusion criteria: Subjects who receives colonoscopy for screening or for clinical purpose Exclusion criteria: Subjects with polyposis, ileus, active GI bleeding, IBD, severe constipation, renal insufficiency, obesity with BMI≥30

Grouping: subjects will be randomized to the following groups:
  1. Group A: 2000 ml PEG-ELS

  2. Group B: 1500ml PEG-ELS with CLRD Randomization process: Random block sheet

Measurements:
  1. Subjects who obey protocol or violate/withdraw protocol will be all recorded.

  2. Parameters concerning patient compliance

  3. Number of detected adenoma and their topographical distribution

  4. Time required for A. Cecal intubation B. Overall procedure time

  5. Colon cleansing effect evaluation

The degree of cleansing will be recorded individually for each bowel segment (rectum, sigmoid colon, descending colon, transverse colon, and ascending colon). Each segment will be rated using a 5-point scale: 4, very good-colon empty and clean; 3, good-presence of clear liquid in the gut; 2, moderate-presence of brown liquid or small amounts of semisolid residual stool, fully removable by suction or displaceable, thus allowing a complete visualization of the underlying mucosa; 1, bad-presence of semisolid stool, only partially removable with a risk of incomplete underlying mucosal visualization; and 0, very bad-presence of semisolid or solid stool, colonoscopy incomplete or has to be stopped. The overall quality of colonic cleansing will be based on the assessment of the individual segments using a scale of A, all segments clean (i.e., scores of 3 or 4 in all segments); B, residual brown liquid or suctionable semisolid stool (i.e., a score of 2) in at least one segment; C, partially removable stool preventing complete visualization of mucosa (i.e., a score of 1) in at least one segment; or D, at least one segment can not be examined due to the presence of solid stool (i.e., a score of 0). A grade of either A or B was defined, a priori, as successful colon cleansing.

Sample size estimation:

Assuming 80% power and significance level at 0.05, totally at least 112 cases will be required for each group (assuming 90% cases in 2000 ml achieving good or excellent preparation and 76% of 1500mL plus low-residue diet achieving the same cleansing effect).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
224 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Diagnostic
Official Title:
Achievement of Better Examinee Compliance on Colon Cleansing Before Colonoscopy Without Sacrificing Cleansing Effect - A Multi-Center Endoscopist-Blinded Randomized Trial Using Commercialized Low-Residue Diet
Study Start Date :
Sep 1, 2008
Anticipated Primary Completion Date :
Jan 1, 2009
Anticipated Study Completion Date :
Jan 1, 2009

Arms and Interventions

Arm Intervention/Treatment
No Intervention: A

PEG-ELS 2000 ml ingestion in the morning of colonoscopy

Other: B

Low-reside diet on previous day (breakfast, lunch and dinner), PEG-ELS 1500 mL in the morning of colonoscopy

Other: Low-residue diet
Commercialized (not yet marketed)low-residue diet

Outcome Measures

Primary Outcome Measures

  1. Colon cleansing level [At the timing of colonoscopy]

Secondary Outcome Measures

  1. adenoma detection rate [At the timing of colonoscopy]

  2. Cecal intubation time [At the timing of colonoscopy]

  3. Patient compliance including abdominal symptoms during colon cleansing, bowel movement on the way to hospital [-2hr]

  4. Whole procedural time [At the timing of colonoscopy]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Subjects who receives colonoscopy for screening or for clinical purpose
Exclusion Criteria:
  • Subjects with polyposis, ileus, active GI bleeding, IBD, severe constipation, renal insufficiency, obesity with BMI≥30

Contacts and Locations

Locations

Site City State Country Postal Code
1 E-DA Hospital Kaohsiung Taiwan
2 Buddhist Tzu-Chi General Hospital Taipei Taiwan
3 En Chu Kong Hospital Taipei Taiwan
4 National Taiwan University Hospital Taipei Taiwan
5 Taipei Medical University Hospital Taipei Taiwan

Sponsors and Collaborators

  • National Taiwan University Hospital
  • Taipei Medical University Hospital
  • E-DA Hospital
  • Buddhist Tzu Chi General Hospital
  • En Chu Kong Hospital

Investigators

  • Principal Investigator: Han-Mo Chiu, MD, National Taiwan University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00748293
Other Study ID Numbers:
  • 200802030R
First Posted:
Sep 8, 2008
Last Update Posted:
Sep 8, 2008
Last Verified:
Sep 1, 2008

Study Results

No Results Posted as of Sep 8, 2008